Christina Peters

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7357648/publications.pdf

Version: 2024-02-01

199	17,438	16451 64	15266 126
papers	citations	h-index	g-index

213	213	213	15593
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	27.0	3,680
2	Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood, 2001, 97, 2962-2971.	1.4	720
3	Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. British Journal of Haematology, 2006, 134, 64-76.	2.5	368
4	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2016, 51, 906-912.	2.4	364
5	Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group. Journal of Clinical Oncology, 2009, 27, 377-384.	1.6	337
6	Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood, 2003, 102, 1114-1120.	1.4	333
7	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet, The, 2012, 379, 1301-1309.	13.7	324
8	Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica, 2014, 99, 811-820.	3.5	302
9	Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation, 2010, 45, 219-234.	2.4	297
10	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectivesâ€"a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2015, 50, 781-789.	2.4	294
11	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood, 2005, 105, 410-419.	1.4	291
12	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplantation, 2015, 50, 1037-1056.	2.4	283
13	X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood, 2011, 117, 53-62.	1.4	268
14	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2012, 47, 770-790.	2.4	256
15	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplantation, 2018, 53, 138-145.	2.4	225
16	Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9590-9595.	7.1	199
17	Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donorsâ€"The ALL-SCT-BFM-2003 Trial. Journal of Clinical Oncology, 2015, 33, 1265-1274.	1.6	186
18	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Journal of Clinical Oncology, 2019, 37, 2246-2256.	1.6	186

#	Article	IF	Citations
19	Human Adult CD34^{â^'} Progenitor Cells Functionally Express the Chemokine Receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but Not CXCR4. Stem Cells and Development, 2005, 14, 329-336.	2.1	183
20	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood, 2013, 122, 4279-4286.	1.4	176
21	Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplantation, 2004, 33, 189-195.	2.4	174
22	The EBMT activity survey: 1990â€“2010. Bone Marrow Transplantation, 2012, 47, 906-923.	2.4	174
23	Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia, 2010, 24, 706-714.	7.2	170
24	Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet, The, 2005, 366, 635-642.	13.7	167
25	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 843.	7.4	166
26	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	1.6	163
27	Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood, 1991, 78, 2780-2784.	1.4	161
28	Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood, 2010, 115, 3437-3446.	1.4	159
29	Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000â€“2010. Bone Marrow Transplantation, 2016, 51, 536-541.	2.4	159
30	Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group. Journal of Clinical Oncology, 2013, 31, 2736-2742.	1.6	149
31	Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood, 2003, 101, 3835-3839.	1.4	148
32	Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplantation, 2014, 49, 744-750.	2.4	145
33	Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood, 2013, 121, 440-446.	1.4	143
34	Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood, 1996, 88, 1089-1097.	1.4	141
35	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)â€“rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood, 2010, 116, 2644-2650.	1.4	141
36	Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplantation, 2008, 42, 679-684.	2.4	131

#	Article	IF	Citations
37	Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. British Journal of Haematology, 1999, 106, 689-696.	2.5	125
38	Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents - a Berlin-Frankfurt-Munster group report. British Journal of Haematology, 2006, 133, 176-182.	2.5	119
39	Superiority of Allogeneic Hematopoietic Stem-Cell Transplantation Compared With Chemotherapy Alone in High-Risk Childhood T-Cell Acute Lymphoblastic Leukemia: Results From ALL-BFM 90 and 95. Journal of Clinical Oncology, 2006, 24, 5742-5749.	1.6	118
40	Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia, 1999, 13, 2060-2069.	7.2	112
41	Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood.. Journal of Clinical Oncology, 1997, 15, 566-573.	1.6	110
42	Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplantation, 2013, 48, 1161-1167.	2.4	110
43	Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial. Journal of Clinical Oncology, 2015, 33, 1275-1284.	1.6	110
44	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. British Journal of Haematology, 2015, 169, 565-573.	2.5	104
45	Atypical teratoid rhabdoid tumor: improved longâ€term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992â€“2012. Cancer Medicine, 2014, 3, 91-100.	2.8	99
46	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia, 2011, 25, 455-462.	7.2	98
47	Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2007, 39, 89-99.	2.4	95
48	Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.. Bone Marrow Transplantation, 1997, 19, 227-231.	2.4	91
49	Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia â€“ Long-term results of trial ALL-REZ BFM P95/96. European Journal of Cancer, 2013, 49, 1346-1355.	2.8	88
50	Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia, 2001, 15, 307-310.	7.2	85
51	Introduction of a Quality Management System and Outcome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 1980-1986.	1.6	85
52	Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood, 2012, 119, 2935-2942.	1.4	82
53	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Advances, 2019, 3, 3393-3405.	5.2	81
54	Rapid discrimination of early CD34+ myeloid progenitors using CD45-RA analysis. Blood, 1993, 81, 2301-2309.	1.4	80

#	Article	IF	Citations
55	Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplantation, 2015, 50, 1542-1550.	2.4	80
56	Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood, 2013, 122, 2135-2141.	1.4	79
57	Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transplantation, 2015, 50, 1168-1172.	2.4	79
58	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	1.4	76
59	Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood, 2009, 113, 5689-5691.	1.4	75
60	Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia, 1999, 13, 2070-2078.	7.2	74
61	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 1574-1581.	3.5	73
62	Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-MÃ¼nster study group. Leukemia, 2009, 23, 1264-1269.	7.2	71
63	Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia, 2010, 24, 2032-2038.	7.2	67
64	Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplantation, 2015, 50, 1536-1541.	2.4	67
65	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	10.7	65
66	Longâ€term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria â€“ A populationâ€based report of the Austrian Berlinâ€Frankfurtâ€MÃ¼nster (BFM) Study Group. British Journal of Haematology, 2009, 144, 559-570.	2.5	61
67	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	2.4	61
68	High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?. Biology of Blood and Marrow Transplantation, 2011, 17, S137-S148.	2.0	60
69	Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia, 2015, 29, 1648-1655.	7.2	59
70	Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood, 2000, 96, 3997-3999.	1.4	57
71	Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia, 2003, 17, 1934-1942.	7.2	57
72	Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation. Therapeutic Drug Monitoring, 2014, 36, 93-99.	2.0	57

#	Article	IF	Citations
73	Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia, 2012, 26, 509-519.	7.2	54
74	Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplantation, 2000, 26, 405-411.	2.4	53
75	G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Annals of Hematology, 1999, 78, 117-123.	1.8	52
76	Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transplantation, 2017, 52, 1406-1415.	2.4	52
77	Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplantation, 2011, 46, 1510-1518.	2.4	51
78	Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWPâ€“EBMT analysis. Leukemia, 2012, 26, 2455-2461.	7.2	51
79	Outcome of relapse after allogeneic <scp>HSCT</scp> in children with <scp>ALL</scp> enrolled in the <scp>ALL</scp>â€<scp>SCT</scp> 2003/2007 trial. British Journal of Haematology, 2018, 180, 82-89.	2.5	50
80	A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Archives of Disease in Childhood, 2012, 97, 185-188.	1.9	49
81	Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplantation, 2008, 41, S71-S74.	2.4	47
82	Stem cell transplantation after reducedâ€intensity conditioning for sickle cell disease. European Journal of Haematology, 2013, 90, 308-312.	2.2	45
83	European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. Pediatric Blood and Cancer, 2016, 63, 139-148.	1.5	45
84	Antithymocyte Globulin Pharmacokinetics in Pediatric Patients After Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2005, 27, 532-536.	0.6	44
85	Allogeneic Stem Cell Transplantation for Pediatric and Adolescent Patients with CML: Results from the Prospective Trial CML-paed I. Klinische Padiatrie, 2009, 221, 351-357.	0.6	44
86	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1629-1642.	2.0	44
87	Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. Bone Marrow Transplantation, 2013, 48, 939-946.	2.4	43
88	Psychosocial adjustment of pediatric patients after allogeneic stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 75-80.	2.4	42
89	Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplantation, 2000, 26, 377-382.	2.4	42
90	Granulocyte Transfusions in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 2009, 31, 166-172.	0.6	42

#	Article	IF	Citations
91	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Annals of Oncology, 2011, 22, 1614-1621.	1.2	42
92	State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29â€“30 September 2015. Bone Marrow Transplantation, 2017, 52, 1029-1035.	2.4	42
93	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?â€”A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	2.4	42
94	Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplantation, 2003, 31, 803-808.	2.4	40
95	Organ toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single centre retrospective analysis. Bone Marrow Transplantation, 1999, 23, 1049-1053.	2.4	39
96	Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplantation, 2005, 35, S9-S11.	2.4	39
97	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	1.8	39
98	Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood, 2010, 116, 1849-1856.	1.4	38
99	Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases. International Archive of Medicine, 2011, 4, 27.	1.2	38
100	Clinical and Immunological Correction of DOCK8 Deficiency by Allogeneic Hematopoietic Stem Cell Transplantation Following a Reduced Toxicity Conditioning Regimen. Pediatric Hematology and Oncology, 2012, 29, 585-594.	0.8	38
101	Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Annals of Hematology, 2015, 94, 297-306.	1.8	38
102	Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL). Journal of Pediatric Hematology/Oncology, 2013, 35, e200-e204.	0.6	37
103	Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biology of Blood and Marrow Transplantation, 2016, 22, 96-103.	2.0	35
104	Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sanguinis, 2003, 85, 322-325.	1.5	34
105	Nonpharmacologic Treatment of Chronic Graft-versus-Host Disease in Children and Adolescents. Biology of Blood and Marrow Transplantation, 2012, 18, S74-S81.	2.0	34
106	Long-term Effects of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Lymphoblastic Leukemia. Current Oncology Reports, 2018, 20, 74.	4.0	32
107	Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. Bone Marrow Transplantation, 1995, 15, 515-21.	2.4	32
108	Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study. Bone Marrow Transplantation, 2014, 49, 1093-1097.	2.4	31

#	Article	IF	Citations
109	Peripheral blood hematopoietic progenitor cells of cytokine-stimulated healthy donors as an alternative for allogeneic transplantation [letter]. Blood, 1994, 83, 3420-3421.	1.4	30
110	Granulocyte transfusions in neutropenic patients: beneficial effects proven?. Vox Sanguinis, 2009, 96, 275-283.	1.5	30
111	Stem Cell Source and Outcome After Hematopoietic Stem Cell Transplantation (HSCT) in Children and Adolescents with Acute Leukemia. Pediatric Clinics of North America, 2010, 57, 27-46.	1.8	30
112	Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2197-2210.	2.0	30
113	Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. International Journal of Radiation Oncology Biology Physics, 1994, 29, 39-44.	0.8	28
114	Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplantation, 2016, 51, 1482-1489.	2.4	28
115	Amphotericin B serum levels in pediatric bone marrow transplant recipients. Bone Marrow Transplantation, 1991, 7, 95-9.	2.4	28
116	Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT. Bone Marrow Transplantation, 2014, 49, 276-279.	2.4	27
117	Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 1848-1855.	2.0	27
118	Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood, 1991, 78, 2780-4.	1.4	27
119	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia, 2020, 34, 2473-2478.	7.2	26
120	Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. Annals of Hematology, 2013, 92, 1121-1128.	1.8	25
121	Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation. Haematologica, 2013, 98, 1804-1809.	3.5	25
122	Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone Marrow Transplantation, 2007, 40, 945-949.	2.4	24
123	Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. Haematologica, 2016, 101, 741-746.	3.5	24
124	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 2020, 34, 1694-1700.	7.2	24
125	Serial granulocytapheresisunder daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. Transfusion, 2001, 41, 390-395.	1.6	23
126	Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica, 2008, 93, 925-929.	3.5	23

#	Article	IF	Citations
127	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1126-1136.	2.4	23
128	Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. British Journal of Cancer, 2013, 109, 2523-2532.	6.4	22
129	Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance. Therapeutic Drug Monitoring, 2018, 40, 84-92.	2.0	22
130	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Pediatrics, 2021, 9, 705179.	1.9	22
131	More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party. Bone Marrow Transplantation, 2017, 52, 1071-1073.	2.4	21
132	ENTEROVIRAL MENINGOENCEPHALITIS IN IMMUNOCOMPROMISED CHILDREN AFTER MATCHED UNRELATED DONOR-BONE MARROW TRANSPLANTATION. Pediatric Hematology and Oncology, 2000, 17, 393-399.	0.8	20
133	Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplantation, 2013, 48, 651-656.	2.4	20
134	Hematopoietic stem cell transplantation for children with acute myeloid leukemiaâ€"results of the AML SCT-BFM 2007 trial. Leukemia, 2020, 34, 613-624.	7.2	19
135	Pediatric acute graftâ€versusâ€host disease prophylaxis and treatment: surveyed realâ€life approach reveals dissimilarities compared to published recommendations. Transplant International, 2020, 33, 762-772.	1.6	19
136	Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia. Annals of Hematology, 2017, 96, 99-106.	1.8	18
137	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. Journal of Clinical Oncology, 2019, 37, 3493-3506.	1.6	18
138	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. Lancet Haematology,the, 2020, 7, e902-e911.	4.6	18
139	Prevalence and Clinical Course of Viral Upper Respiratory Tract Infections in Immunocompromised Pediatric Patients With Malignancies or After Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2012, 34, 442-449.	0.6	17
140	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 666-669.	2.0	17
141	Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL. Bone Marrow Transplantation, 2019, 54, 1847-1858.	2.4	16
142	A Web-Based Mobile App (INTERACCT App) for Adolescents Undergoing Cancer and Hematopoietic Stem Cell Transplantation Aftercare to Improve the Quality of Medical Information for Clinicians: Observational Study. JMIR MHealth and UHealth, 2020, 8, e18781.	3.7	15
143	Flow cytometric monitoring of hematopoietic reconstitution in myeloablated patients following allogeneic transplantation. Cytotherapy, 1999, 1, 295-309.	0.7	14
144	National Institutes of Healthâ€"Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution. Frontiers in Immunology, 2019, 10, 1879.	4.8	14

#	Article	IF	Citations
145	Resolution of early cytomegalovirus (CMV) infection after leukocyte transfusion therapy from a CMV seropositive donor. Bone Marrow Transplantation, 1998, 22, 289-292.	2.4	13
146	Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics Journal, 2018, 18, 64-69.	2.0	13
147	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics, 2021, 9, 784024.	1.9	13
148	Busulfanâ€“fludarabine- or treosulfanâ€“fludarabine-based myeloablative conditioning for children with thalassemia major. Annals of Hematology, 2022, 101, 655-665.	1.8	13
149	Low incidence of symptomatic osteonecrosis after allogeneic <scp>HSCT</scp> in children with highâ€risk or relapsed <scp>ALL</scp> â€“ results of the <scp>ALL</scp>â€<scp>SCT</scp> 2003 trial. British Journal of Haematology, 2018, 183, 104-109.	2.5	12
150	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective Iâ€BFM analysis of 333 children. British Journal of Haematology, 2020, 189, 745-750.	2.5	12
151	Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases. Bone Marrow Transplantation, 1998, 22, 431-437.	2.4	11
152	Extramedullary Relapse Despite Graft-Versus-Leukemia Effect after Bone Marrow Transplantation in a Girl with Juvenile Myelornonocytic Leukemia. Leukemia and Lymphoma, 1999, 33, 597-600.	1.3	11
153	Survey on haematopoietic stem cell transplantation for children in Europe. Bone Marrow Transplantation, 2005, 35, S3-S8.	2.4	11
154	Strategies of the donor search for children with second CR ALL lacking a matched sibling donor. Bone Marrow Transplantation, 2008, 41, S75-S79.	2.4	11
155	Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP. Bone Marrow Transplantation, 2015, 50, 592-597.	2.4	11
156	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
157	The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplantation, 2021, 56, 257-266.	2.4	11
158	Rothia mucilaginosa bacteremia: A 10â€year experience of a pediatric tertiary care cancer center. Pediatric Blood and Cancer, 2019, 66, e27691.	1.5	10
159	The Present Role of Bone Marrow and Stem Cell Transplantation in the Therapy of Children with Acute Leukemia. Annals of the New York Academy of Sciences, 1997, 824, 38-64.	3.8	9
160	Lethal Pulmonary Complications After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Pediatric Infectious Disease Journal, 2012, 31, 115-119.	2.0	9
161	Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemiaâ€"A prospective international multicenter trial on behalf of the BFMâ€SG and the EBMTâ€PDWP. American Journal of Hematology, 2019, 94, 880-890.	4.1	9
162	Long-term remission in pediatric Wegener granulomatosis following allo-SCT after reduced-intensity conditioning. Bone Marrow Transplantation, 2011, 46, 462-463.	2.4	7

#	Article	IF	Citations
163	Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1448-1450.	2.0	7
164	Allogeneic Hematopoietic Stem Cell Transplantation to Cure Transfusion-Dependent Thalassemia: Timing Matters!. Biology of Blood and Marrow Transplantation, 2018, 24, 1107-1108.	2.0	7
165	High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2020, 55, 376-383.	2.4	7
166	Another step forward towards improved outcome after HLA-haploidentical stem cell transplantation. Leukemia, 2004, 18, 1769-1771.	7.2	6
167	Multiple small versus few large amount aspirations for bone marrow harvesting in autologous and allogeneic bone marrow transplantation. Transfusion and Apheresis Science, 2016, 55, 221-224.	1.0	6
168	Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e27-e37.	2.0	6
169	Exhaled nitric oxide and pulmonary complications after paediatric stem cell transplantation. European Journal of Pediatrics, 2012, 171, 1095-1101.	2.7	5
170	Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, 96-102.	2.0	5
171	Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. Memo - Magazine of European Medical Oncology, 2020, 13, 27-31.	0.5	5
172	Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphomaâ€"A Report from the ALL-REZ Study Group. Journal of Clinical Medicine, 2021, 10, 5292.	2.4	5
173	A single Centre Experience with allogeneic Stem Cell Transplantation for Severe Aplastic Anaemia in Childhood. Klinische Padiatrie, 1997, 209, 201-208.	0.6	4
174	Standards of Stem Cell Transplantation: Part I: The Accreditation of Paediatric Stem Cell Transplantation Centres within the EBMT; Part II: Intensive Care Units in Paediatric Stem Cell Transplantation; Part III: Informed Consent and Sibling Donor Issues. Bone Marrow Transplantation, 2001, 28, S4-S5.	2.4	4
175	T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. International Journal of Laboratory Hematology, 2007, 30, 071115151007004-???.	1.3	4
176	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. Blood Advances, 2019, 3, 3143-3156.	5.2	4
177	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	4
178	Allogeneic bone marrow transplantation-mediated transfer of specific immunity against Toxocara canis associated with excessive IgE. Bone Marrow Transplantation, 2001, 28, 519-521.	2.4	3
179	Influence of transplantation regimen on prognostic significance of high-level minimal residual disease before allogeneic stem cell transplantation in children with ALL. Bone Marrow Transplantation, 2001, 28, 1087-1089.	2.4	3
180	Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies. Pediatric Hematology and Oncology, 2019, 36, 494-503.	0.8	3

#	Article	IF	Citations
181	Transfer and loss of allergenâ€specific responses via stem cell transplantation: A prospective observational study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2243-2253.	5.7	3
182	Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children. Wiener Klinische Wochenschrift, 2021, 133, 41-51.	1.9	3
183	ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	2.4	3
184	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2022, 198, 24-45.	2.5	3
185	Non-atopic IgE and eosinophil cationic protein after allogeneic hematopoietic stem cell transplantation in children. Annals of Hematology, 2012, 91, 949-956.	1.8	2
186	Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood, 1991, 78, 2780-2784.	1.4	2
187	Reduction of Treatment Related Mortality After Stem Cell Transplantation In Children and Adolescents with all Undergoing Allogeneic Stem Cell Transplantation: The Value Of Severe Adverse Event Reporting. Biology of Blood and Marrow Transplantation, 2009, 15, 80.	2.0	1
188	Human Leukocyte Antigen Distribution in German Caucasians with Advanced Ewingâ€™s Sarcoma. Klinische Padiatrie, 2012, 224, 353-358.	0.6	1
189	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. American Journal of Hematology, 2021, 96, 719-726.	4.1	1
190	Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood, 2000, 96, 3997-3999.	1.4	1
191	Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study. Blood, 2017, 130, 911-911.	1.4	1
192	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics Journal, 2022, 22, 9-18.	2.0	1
193	Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). Therapeutic Advances in Hematology, 2022, 13, 204062072210994.	2.5	1
194	Neue Formen der Stammzelltransplantation. Monatsschrift Fur Kinderheilkunde, 2003, 151, 146-153.	0.1	0
195	The EBMT Paediatric Diseases Working Party: current concepts and future aims. Memo - Magazine of European Medical Oncology, 2009, 2, 178-181.	0.5	0
196	USABILITY TESTING THE GERIATRIC SCHOLARS QUALITY IMPROVEMENT DASHBOARDS. Innovation in Aging, 2018, 2, 815-816.	0.1	0
197	Probleme der Schmerztherapie im Kindesalter. , 2001, , 257-271.		0
198	Rational Response-Adapted Risk Stratification and Treatment for Children with Late Bone Marrow Relapses of B-Cell Precursor Acute Lymphoblastic Leukaemia: A Report from the ALL-REZ BFM Trial Group. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
199	Safe transfer of pediatric patients from hematopoietic stem cell transplant unit into the pediatric intensive care unit: views of nurses and physicians. Bone Marrow Transplantation, 2022, , .	2.4	0